| abstract |
A process is provided comprising the use of novel fermentation and chromatographic procedures separately and jointly for the production of new molecular analogues of recombinant human erythropoietin (r'-HuEPO), which have a longer half-life compared to r-HuEPO, in biologically active form from fluids, especially mammalian host cell culture supernatants; wherein said analogues have a differential glycosylation pattern and contain sialic acid residues approximately ranging from 14-18. New molecular analogues of recombinant human erythropoietin r-HuEPO are also provided. • |